Jeppe Zacho

Medicine · Health Sciences

26h-index3.7kcitations48works1.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Diabetes Treatment and Management(22), Diabetes Management and Research(15), Metabolism, Diabetes, and Cancer(14), Adipokines, Inflammation, and Metabolic Diseases(9), Genetic Associations and Epidemiology(5)

Publications48 total

SAT-201 Phase 3 randomised, placebo-controlled ESSENCE trial of semaglutide 2.4 mg in participants with non-cirrhotic non-alcoholic steatohepatitis: baseline characteristics, impact of new metabolic dysfunction-associated steatotic liver disease criteria and non-invasive tests
Journal of Hepatology·2024· 1 cited
Incorporating and interpreting regulatory guidance on estimands in diabetes clinical trials: The PIONEER 1 randomized clinical trial as an example
Diabetes Obesity and Metabolism·2019· 64 citedOpen Access
Author response for "Incorporating and Interpreting Regulatory Guidance on Estimands in Diabetes Clinical Trials: The PIONEER 1 Randomized Clinical Trial as an Example"
2019
Author response for "Incorporating and Interpreting Regulatory Guidance on Estimands in Diabetes Clinical Trials: The PIONEER 1 Randomized Clinical Trial as an Example"
2019
Greater Combined Reductions in Hba1C ≥1.0% and Weight ≥5.0% with Semaglutide Versus Comparators in type 2 Diabetes
Endocrine Practice·2019· 19 cited
A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin
Diabetes Care·2018· 78 cited
Semaglutide s.c. Once-Weekly in Type 2 Diabetes: A Population Pharmacokinetic Analysis
Diabetes Therapy·2018· 37 citedOpen Access
Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme
Diabetes Obesity and Metabolism·2018· 21 citedOpen Access
Exposure‐response analysis for evaluation of semaglutide dose levels in type 2 diabetes
Diabetes Obesity and Metabolism·2018· 45 citedOpen Access
Mehr Patienten unter Semaglutid erreichten ein HbA1c unter 7% ohne Gewichtszunahme, Hypoglykämie und gastrointestinale Ereignisse, im Vergleich zu Komparatoren in den Studien SUSTAIN 1 – 5
Diabetologie und Stoffwechsel·2018
Bewertung der Semaglutid-Dosierungen bei Typ 2 Diabetes auf Grundlage von Populationspharmakokinetik und Expositions-Response
Diabetologie und Stoffwechsel·2018
A Randomized Trial Investigating the Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Semaglutide Once-Weekly in Healthy Male Japanese and Caucasian Subjects
Advances in Therapy·2018· 26 citedOpen Access
Reproductive outcome of patients undergoing in vitro fertilisation treatment and diagnosed with bacterial vaginosis or abnormal vaginal microbiota: a systematic <scp>PRISMA</scp> review and meta‐analysis
BJOG An International Journal of Obstetrics & Gynaecology·2018· 114 cited
Etudes SUSTAIN 1-5 : plus de patients sous semaglutide atteignent un taux dâHbA1c < 7 % sans prise de poids, hypoglycémies ou effets indésirables gastro-intestinaux
2018
Cover Image, Volume 20, Issue 2
Diabetes Obesity and Metabolism·2018Open Access
Safety and efficacy of once‐weekly semaglutide vs additional oral antidiabetic drugs in Japanese people with inadequately controlled type 2 diabetes: A randomized trial
Diabetes Obesity and Metabolism·2018· 110 citedOpen Access
Semaglutide Reduces HbA1c and Body Weight Across Multiple Background OAD Treatment Categories
Canadian Journal of Diabetes·2017
Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in <scp>J</scp> apanese people with type 2 diabetes
Diabetes Obesity and Metabolism·2017· 108 citedOpen Access
Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine in insulin-naïve subjects with type 2 diabetes (SUSTAIN 4)
Diabetes Research and Clinical Practice·2016· 2 cited
Insulin degludec/insulin aspart vs biphasic insulin aspart 30 twice daily in Japanese patients with type 2 diabetes: A randomized controlled trial
Journal of Diabetes Investigation·2016· 10 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Børge G. Nordestgaard(17), Anne Tybjærg‐Hansen(15), Vanita R. Aroda(8), George Davey Smith(7), Bertrand Cariou(6), Nicholas J. Timpson(5), Marianne Benn(4), Tomoyuki Nishida(4), Thomas R. Pieber(4), Anne Flint(4), Srikanth Bellary(4), Peer Grande(3), Debbie A. Lawlor(3), Roger Harbord(3), Tom Palmer(3), Yutaka Seino(3), Cyrus Desouza(3), Trine Saugstrup(3), John B. Buse(3), Morten Donsmark(3)